| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| Other Sizes |
| Targets |
Ritalinic acid is a metabolite of the psychostimulant drugs methylphenidate, dexmethylphenidate, and ethylphenidate. The primary targets of these parent drugs are the dopamine and norepinephrine transporters in the brain. Ritalinic acid itself is pharmacologically inactive and serves as a biomarker for methylphenidate exposure and metabolism.
|
|---|---|
| ln Vitro |
Ritalinic acid is pharmacologically inactive and does not exhibit significant biological activity. It is studied for its role in the metabolism of psychostimulant drugs. In vitro, it is used as a reference standard for quantifying methylphenidate and its metabolites in biological samples.
|
| ln Vivo |
In vivo, Ritalinic acid is the major inactive urinary metabolite of methylphenidate. It is excreted in urine and serves as a biomarker for monitoring therapeutic drug levels and investigating metabolic pathways of central nervous system stimulants. Its presence in urine indicates methylphenidate exposure and metabolism.
|
| Enzyme Assay |
In vitro assays for Ritalinic acid typically involve its use as a reference standard in LC-MS/MS or GC-MS methods for quantifying methylphenidate and its metabolites in biological samples. The compound is spiked into plasma or urine samples to create calibration curves. Its chemical stability and chromatographic properties are characterized under various analytical conditions.
|
| Cell Assay |
For in vitro cell assays, Ritalinic acid is not typically used as a treatment. Instead, it is measured in cell culture supernatants or lysates as a metabolite of methylphenidate. Cells (e.g., hepatocytes or brain-derived cells) are treated with methylphenidate, and Ritalinic acid production is quantified by LC-MS/MS to study drug metabolism and enzyme activity.
|
| Animal Protocol |
For in vivo animal studies, Ritalinic acid is typically measured in urine and plasma samples from rodents or other animals administered methylphenidate. The compound is quantified by LC-MS/MS to assess the pharmacokinetics and metabolism of methylphenidate. Its urinary excretion profile is used to study the metabolic pathways and elimination of psychostimulant drugs.
|
| ADME/Pharmacokinetics |
Ritalinic acid (MW 219.28) has the molecular formula C13H17NO2. It is a white crystalline solid that is pharmacologically inactive. The compound is stable under recommended storage conditions (typically -20°C). As the primary metabolite of methylphenidate, it is excreted in urine and serves as a biomarker for drug exposure.
|
| Toxicity/Toxicokinetics |
Ritalinic acid is for research use only. As an inactive metabolite of the approved drug methylphenidate, it is not expected to exhibit significant toxicity at physiological concentrations. However, it is used in toxicological studies to monitor drug exposure and metabolism. Standard laboratory safety precautions should be followed.
|
| References |
[1]. Ricardo Jorge Dinis-Oliveira, et al. Metabolomics of Methylphenidate and Ethylphenidate: Implications in Pharmacological and Toxicological Effects. Eur J Drug Metab Pharmacokinet. 2017 Feb;42(1):11-16.
|
| Additional Infomation |
Ritalinic acid is a monocarboxylic acid, formed by the substitution of phenylacetic acid at the 2-position with a piperidine-2-yl group. It is a metabolite of the drug methylphenidate. It is both a metabolite of marine xenobiotics and a drug metabolite. It is a monocarboxylic acid belonging to the piperidine class of compounds.
Ritalinic acid (CAS# 19395-41-6) is the primary inactive urinary metabolite of methylphenidate, a drug used for ADHD and narcolepsy. It has not been approved as a therapeutic agent. The compound is widely used in forensic toxicology, pharmacokinetics research, and as a reference standard for monitoring therapeutic drug levels. It is a monocarboxylic acid substituted by a piperidin-2-yl group at position 2. |
| Molecular Formula |
C13H17NO2
|
|---|---|
| Molecular Weight |
219.28
|
| Exact Mass |
219.125
|
| CAS # |
19395-41-6
|
| PubChem CID |
86863
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
367.7±17.0 °C at 760 mmHg
|
| Melting Point |
236-238ºC
|
| Flash Point |
176.2±20.9 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.554
|
| LogP |
2.08
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
16
|
| Complexity |
236
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C(C([H])(C1C([H])=C([H])C([H])=C([H])C=1[H])C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])N1[H])=O
|
| InChi Key |
INGSNVSERUZOAK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H17NO2/c15-13(16)12(10-6-2-1-3-7-10)11-8-4-5-9-14-11/h1-3,6-7,11-12,14H,4-5,8-9H2,(H,15,16)
|
| Chemical Name |
2-phenyl-2-piperidin-2-ylacetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5604 mL | 22.8019 mL | 45.6038 mL | |
| 5 mM | 0.9121 mL | 4.5604 mL | 9.1208 mL | |
| 10 mM | 0.4560 mL | 2.2802 mL | 4.5604 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
